MiMedx (MDXG) Q2 2026 Earnings Call Transcript

MiMedx reported Q2 2026 revenue of $64.4M, down 35% YoY but up 9% sequentially, with Surgical revenue up 15% YoY to $39.3M while Wound revenue fell 61% YoY to $25.1M due to Medicare reimbursement changes. Profitability remains pressured (GAAP net loss of $14.8M; adjusted EBITDA loss of $8.1M) despite sequential improvement toward breakeven as cost reductions take effect, alongside a $5M incremental bad-debt expense. In a major strategic shift, MiMedx signed a definitive agreement to acquire Sanara MedTech for ~$350M ($35/share) funded with a $300M Hayfin term loan (SOFR + 6.25%), targeting 2027 combined revenue >$400M and adjusted EBITDA margin >20% with at least $20M annualized synergies and leverage under 3x by the end of the first full year.

Analysis

The investment case is less about one soft quarter and more about a mix reset: MDXG is trying to reprice itself from a reimbursement-sensitive wound name into a surgical franchise with better visibility and higher controllability. That can support multiple expansion if the market believes the surgical mix is durable, but the bond market is implicitly telling you the deal is not free — 6.25% over SOFR is expensive capital, so equity value creation depends on real integration savings, not just headline synergy claims.

Near term, the stock should trade on proof points rather than narrative: Q3 gross margin recovery into the mid-70s, no repeat bad-debt hit, and evidence that June was a run-rate rather than a catch-up month. If those do not show up, MDXG reverts to a low-growth medtech with leverage and execution risk. The main losers are smaller wound-care competitors and office-based accounts that are least able to absorb reimbursement friction; the main second-order winner is hospital/outpatient channel share concentration, which favors operators with stronger clinical data and broader sales coverage.

The contrarian miss is that the market may be underestimating how much of the 2027 story is already dependent on a relatively clean regulatory and integration path. Any slippage in the Sanara close, a delay in 510(k) approvals, or a reversal in claims processing would expose that 2026 is still a reset year, not a true inflection. The thesis is falsified if Q3 volume does not sustain, EBITDA does not turn positive by Q4, or if leverage/financing costs force the company to slow reinvestment just as it needs to scale the new portfolio.

Key Decisions for Investors

• MDXG: Buy only on post-earnings weakness, not into strength; use a 1-3 month horizon and require confirmation that Q3 gross margin returns to the mid-70s and bad debt does not reappear. Upside is in a mix rerate, but stop out if EBITDA stays negative through Q4.
• SMTI / MDXG merger-arb watch: If Sanara trades more than ~8% below implied consideration after accounting for the stock component, consider a light long SMTI / short MDXG hedge. Catalyst is year-end close; key risk is financing, regulatory delay, or a wider spread on integration skepticism.
• Watch-list alert on MDXG: if the next monthly sales print falls materially below the June pace, fade the 'stabilization' narrative. That would imply the sequential improvement was claim-timing noise, not real demand recovery.
• Avoid shorting MDXG solely on the revenue decline; the cleaner short would have been pre-deal wound-only exposure. Post-announcement, the stock has self-help optionality, and the risk/reward on a naked short is worse unless the financing/covenant story deteriorates.